Cover Image
市場調查報告書

腫瘤切除的全球市場的預測 (∼2021年):各技術 (高頻、微波、冷凍、IRE、超音波、雷射)、治療方式、對象疾病

Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecast 2021

出版商 MarketsandMarkets 商品編碼 335087
出版日期 內容資訊 英文 261 Pages
訂單完成後即時交付
價格
Back to Top
腫瘤切除的全球市場的預測 (∼2021年):各技術 (高頻、微波、冷凍、IRE、超音波、雷射)、治療方式、對象疾病 Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecast 2021
出版日期: 2016年10月05日 內容資訊: 英文 261 Pages
簡介

全球腫瘤切除的市場預計從2016年到2021年以12.5%的年複合成長率發展,2021年成長到5億8010萬美元的規模。現在雖然是北美,歐洲成熟市場佔最大的佔有率,但是今後預計亞太地區將達成最大的成長。以有效性和安全性的強化的焦點的技術發展,最小侵入性技術的需求擴大,全球的癌症患者數的增加,R&D支援的官民倡議和資金供給的擴大等,成為促進該市場成長的要素。

本報告提供全球腫瘤切除的市場調查,市場及技術概要,產業結構與價值鏈,市場成長的各種影響因素及市場機會分析,各技術、治療方式、對象疾病趨勢及市場規模的變化與預測,地區及主要國家趨勢,競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 市場機會
  • 北美:最大的地區佔有率
  • 主導中國、印度:在預測期間內的市場成長
  • 中國、印度:預計推動微波、冷凍切除產品的需求
  • 肝癌:最大的各對象疾病佔有率
  • MEDTRONIC:市場中心的地位

第5章 腫瘤切除的全球市場:概要

  • 簡介
  • 市場發展的變化
  • 市場動態
    • 影響分析
    • 成長推動因素
    • 阻礙成長要素
    • 市場機會
    • 課題

第6章 腫瘤切除的全球市場:產業分析

  • 簡介
  • 價值鏈分析
  • 產業趨勢
  • 波特的五力分析

第7章 腫瘤切除的全球市場:各技術

  • 簡介
  • 射頻消融術
  • 微波切除
  • 冷凍切除
  • 其他

第8章 腫瘤切除的全球市場:各治療模式

  • 簡介
  • 外科的切除
  • 腹腔鏡下切除
  • 經皮切除

第9章 腫瘤切除的全球市場:各對象疾病

  • 簡介
  • 肝癌
  • 肺癌
  • 腎臟癌
  • 骨轉移腫瘤
  • 其他

第10章 腫瘤切除的全球市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 義大利
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他
  • 其他

第11章 競爭環境

  • 簡介
  • 市場佔有率分析
  • 競爭模式
  • 近幾年的發展趨勢
    • 管道開發、產品的強化
    • 投資撤退、收購
    • 地區的擴張
    • 協定、聯盟、合作
    • 其他

第12章 企業簡介

  • 簡介
  • ANGIODYNAMICS, INC.
  • BOSTON SCIENTIFIC CORPORATION
  • GALIL MEDICAL, INC.
  • EDAP TMS S.A.
  • HEALTHTRONICS, INC. (ALTARIS CAPITAL PARTNERS, LLC)
  • MEDTRONIC PLC
  • MERMAID MEDICAL, INC.
  • MISONIX, INC.
  • NEUWAVE MEDICAL, INC. (ETHICON - J&J GROUP OF COMPANY)
  • SONACARE MEDICAL, LLC

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 3271

The global tumor ablation market is estimated to register a high CAGR of 12.5% during 2016-2021, and is expected to be valued at ~USD 580.1 million in 2021. Although mature markets (North America and Europe) held large shares of the tumor ablation market in 2016, the Asia-Pacific region is projected to register the highest growth during the next five years. A number of factors such as technological advancements in the field of tumor ablation focused on enhancing effectiveness and safety of the treatment, rising demand of minimal invasive tumor ablation techniques, increasing prevalence of cancer across the globe, and growing public-private initiatives and funding to support R&D activities in tumor ablation are propelling the growth of the market. However, factors such as unfavorable regulatory policies and cost-containment measures adopted by various governments are restraining the optimal market growth.

On the basis of technology, the global tumor ablation market is divided into four major categories, namely, radiofrequency ablation, microwave ablation, cryoablation, and others (includes electrical, laser/light, ultrasound). Based on mode of treatment, the tumor ablation market is segmented into surgical mode, laparoscopic mode, and percutaneous mode. On the basis of application of tumor ablation, the market is categorized into liver cancer, lung cancer, kidney/renal cancer, bone metastasis, and others (includes tumor ablation for the treatment of prostate, breast, colorectal, thyroid, pancreas, neuroendocrine, head, neck, and lumbar-vertebra cancer).

Geographically, North America is estimated to command the largest share of the global tumor ablation market in 2016, followed by Europe. The high prevalence and incidence of major types of cancer (such as liver, lung, kidney, and bone metastasis) in the region, rising inclination of patients towards minimally invasive procedures for cancer treatment, and increasing government funding for cancer research are market drivers in North America. However, unsupportive government policies, limited availability of medical reimbursements in the U.S., and cost-containment measures adopted by governments in the U.S. and Canada are negatively affecting the growth of the tumor ablation market in this region.

The tumor ablation market is fairly competitive, with a large number of global and local manufacturers of tumor ablation solutions. Medtronic plc (Ireland), AngioDynamics, Inc. (U.S.), and HealthTronics, Inc. (U.S.) were the top three players in the tumor ablation market in 2015. New product launches and product enhancements; acquisitions; geographic expansions; and partnerships, agreements, and collaborations are the major strategies adopted by most players to achieve growth in the tumor ablation market.

Benefits of Buying the Report:

This report studies tumor ablation market based on technologies, modes of treatment, and applications. The report also studies, factors (such as drivers, restraints, opportunities, and challenges) which positively and negatively affect market growth. It analyzes opportunities and challenges in the market for stakeholders, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes the micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. GEOGRAPHIC SCOPE
    • 1.3.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. KEY DATA FROM SECONDARY SOURCES
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.2. OPPORTUNITY INDICATORS
    • 2.2.1. DEMAND-SIDE ANALYSIS
    • 2.2.2. SUPPLY-SIDE ANALYSIS
  • 2.3. MARKET SIZE ESTIMATION
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. RESEARCH ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT MARKET SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. MARKET OPPORTUNITIES FOR GROWTH IN TUMOR ABLATION MARKET (2016-2021)
  • 4.2. NORTH AMERICA TO COMMAND THE LARGEST SHARE OF TUMOR ABLATION MARKET FOR ALL MODES OF TREATMENT (2016)
  • 4.3. CHINA AND INDIA TO LEAD THE MARKET GROWTH FOR TUMOR ABLATION TECHNOLOGIES DURING THE FORECAST PERIOD
  • 4.4. CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR MICROWAVE AND CRYOABLATION-BASED TUMOR ABLATION PRODUCTS (2016-2021)
  • 4.5. LIVER CANCER HOLDS THE LARGEST SHARE IN TUMOR ABLATION MARKET IN 2016
  • 4.6. MEDTRONIC, PLC DOMINATED THE TUMOR ABLATION MARKET IN 2015

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET EVOLUTION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. IMPACT ANALYSIS
    • 5.3.2. KEY MARKET DRIVERS
      • 5.3.2.1. RISING PREVALENCE OF CANCER
      • 5.3.2.2. TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF THERMAL ABLATION
      • 5.3.3.3. RISING MARKET DEMAND FOR MINIMALLY INVASIVE SURGERIES
      • 5.3.3.4. INCREASING PUBLIC-PRIVATE FUNDING FOR PRODUCT DEVELOPMENT AND COMMERCIALIZATION
      • 5.3.3.5. GROWING NUMBER OF HOSPITALS AND SURGICAL & ABLATION CENTERS
    • 5.3.3. KEY MARKET RESTRAINTS
      • 5.3.3.1. UNFAVORABLE REGULATORY SCENARIO
      • 5.3.3.2. COST-CONTAINMENT MEASURES ADOPTED BY VARIOUS REGIONAL GOVERNMENTS
    • 5.3.4. KEY MARKET OPPORTUNITIES
      • 5.3.4.1. IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES
      • 5.3.4.2. INCREASING PATIENT AWARENESS ABOUT THE THERAPEUTIC BENEFITS OF TUMOR ABLATION
      • 5.3.4.3. EVOLVING REIMBURSEMENT SCENARIO
    • 5.3.5. KEY MARKET CHALLENGES
      • 5.3.5.1. THERAPEUTIC CHALLENGES RELATED TO TUMOR ABLATION PROCEDURES

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. INDUSTRY TRENDS
    • 6.3.1. GROWING ADOPTION RATE OF RADIOFREQUENCY-BASED TUMOR ABLATION PROCEDURES
    • 6.3.2. GROWING MARKET FOCUS ON THE DEVELOPMENT OF NOVEL MICROWAVE-BASED TUMOR ABLATION PRODUCTS
  • 6.4. PORTER'S FIVE FORCE ANALYSIS
    • 6.4.1. OVERVIEW
    • 6.4.2. THREAT FROM NEW ENTRANTS
    • 6.4.3. THREAT OF SUBSTITUTES
    • 6.4.4. BARGAINING POWER OF SUPPLIERS
    • 6.4.5. BARGAINING POWER OF BUYERS
    • 6.4.6. INTENSITY OF COMPETITIVE RIVALRY

7. TUMOR ABLATION TECHNOLOGY MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. RADIOFREQUENCY (RF) ABLATION
  • 7.3. MICROWAVE ABLATION
  • 7.4. CRYOABLATION
  • 7.5. OTHER TECHNOLOGIES

8. TUMOR ABLATION TECHNOLOGY MARKET, BY MODE OF TREATMENT

  • 8.1. INTRODUCTION
  • 8.2. SURGICAL ABLATION
  • 8.3. LAPAROSCOPIC ABLATION
  • 8.4. PERCUTANEOUS ABLATION

9. TUMOR ABLATION TECHNOLOGY MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. LIVER CANCER ABLATION
  • 9.3. LUNG CANCER ABLATION
  • 9.4. KIDNEY CANCER ABLATION
  • 9.5. BONE METASTASIS ABLATION
  • 9.6. OTHER APPLICATIONS

10. TUMOR ABLATION TECHNOLOGY MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. ITALY
    • 10.3.2. GERMANY
    • 10.3.3. FRANCE
    • 10.3.4. U.K.
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE (ROE)
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA-PACIFIC (ROAPAC)
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET SHARE ANALYSIS, BY KEY PLAYER (2015)
  • 11.3. COMPETITIVE SCENARIO
  • 11.4. RECENT DEVELOPMENTS
    • 11.4.1. PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS
    • 11.4.2. DIVESTMENTS AND ACQUISITIONS
    • 11.4.3. GEOGRAPHIC EXPANSION
    • 11.4.4. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.4.5. OTHER DEVELOPMENTS

12. COMPANY PROFILES

  • 12.1. INTRODUCTION
    • 12.1.1. GEOGRAPHIC BENCHMARKING
    • 12.1.2. KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
  • 12.2. ANGIODYNAMICS, INC. (U.S.)
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. MNM VIEW
    • 12.2.3. ANGIODYNAMICS, INC.-COMPANY SNAPSHOT
    • 12.2.4. PRODUCT PORTFOLIO
    • 12.2.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.3. BOSTON SCIENTIFIC CORPORATION (U.S)
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. MNM VIEW
    • 12.3.3. BOSTON SCIENTIFIC CORPORATION-COMPANY SNAPSHOT
    • 12.3.4. PRODUCT PORTFOLIO
    • 12.3.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.4. GALIL MEDICAL, INC. (U.S.)
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. MNM VIEW
    • 12.4.3. BTG INTERNATIONAL LTD.- COMPANY SNAPSHOT
    • 12.4.4. PRODUCT PORTFOLIO
    • 12.4.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.5. EDAP TMS S.A. (FRANCE)
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. EDAP TMS S.A.-COMPANY SNAPSHOT*
    • 12.5.3. PRODUCT PORTFOLIO
    • 12.5.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.6. HEALTHTRONICS, INC. (U.S.) [A BUSINESS SEGMENT OF ALTARIS CAPITAL PARTNERS, LLC (U.S.)]
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. MNM VIEW
    • 12.6.3. PRODUCT PORTFOLIO
    • 12.6.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.7. MEDTRONIC PLC (IRELAND)
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. MNM VIEW
    • 12.7.3. MEDTRONIC PLC-COMPANY SNAPSHOT
    • 12.7.4. PRODUCT PORTFOLIO
    • 12.7.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.8. MERMAID MEDICAL, INC. (DENMARK)
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. PRODUCT PORTFOLIO
    • 12.8.3. RECENT DEVELOPMENTS (2013-2016)
  • 12.9. MISONIX, INC. (U.S)
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. MISONIX, INC.-COMPANY SNAPSHOT
    • 12.9.3. PRODUCT PORTFOLIO
    • 12.9.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.10. NEUWAVE MEDICAL, INC. (U.S) (ACQUIRED BY ETHICON-J&J GROUP OF COMPANY)
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. PRODUCT PORTFOLIO
    • 12.10.3. RECENT DEVELOPMENTS (2013-2016)
  • 12.11. SONACARE MEDICAL, LLC (U.S)
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. PRODUCT PORTFOLIO
    • 12.11.4. RECENT DEVELOPMENTS (2013-2016)

13. APPENDIX

  • 13.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE-1: GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION) UU
  • TABLE-2: TUMOR ABLATION MARKET SIZE FOR RF ABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-3: TUMOR ABLATION MARKET SIZE FOR MICROWAVE ABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-4: TUMOR ABLATION MARKET SIZE FOR CRYOABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-5: TUMOR ABLATION MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-6: GLOBAL TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-7: CLINICAL PERSPECTIVE OF KEY HEPATOCELLULAR CARCINOMA SURGICAL TREATMENT MODES-A COMPARATIVE STUDY
  • TABLE-8: TUMOR ABLATION MARKET SIZE FOR SURGICAL MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-9: TUMOR ABLATION MARKET SIZE FOR LAPAROSCOPIC MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-10: TUMOR ABLATION MARKET SIZE FOR PERCUTANEOUS MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-11: KEY PERCUTANEOUS TUMOR ABLATION TECHNOLOGIES-A COMPARATIVE STUDY
  • TABLE-12: GLOBAL TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-13: TUMOR ABLATION MARKET SIZE FOR LIVER CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-14: LIVER CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-15: TUMOR ABLATION MARKET SIZE FOR LUNG CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-16: LUNG CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-17: TUMOR ABLATION MARKET SIZE FOR KIDNEY CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-18: KIDNEY CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-19: TUMOR ABLATION MARKET SIZE FOR BONE METASTASIS APPLICATION, Y REGION, 2014-2021 (USD MILLION)
  • TABLE-20: BONE METASTASIS ABLATION MARKET-INFLUENCING FACTORS
  • TABLE-21: TUMOR ABLATION MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-22: GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE-23: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE-24: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-25: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-26: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-27: U.S.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-28: U.S.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-29: U.S.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-30: CANADA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-31: CANADA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-32: CANADA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-33: EUROPE: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE-34: EUROPE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-35: EUROPE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-36: EUROPE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-37: ITALY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-38: ITALY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-39: ITALY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-40: GERMANY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-41: GERMANY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-42: GERMANY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-43: FRANCE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014- 2021 (USD MILLION)
  • TABLE-44: FRANCE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-45: FRANCE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-46: U.K.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-47: U.K.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-48: U.K.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-49: SPAIN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-50: SPAIN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-51: SPAIN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-52: ROE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-53: ROE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-54: ROE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-55: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE-56: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-57: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-58: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-59: JAPAN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-60: JAPAN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-61: JAPAN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-62: CHINA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-63: CHINA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-64: CHINA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-65: INDIA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-66: INDIA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-67: INDIA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-68: ROAPAC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-69: ROAPAC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-70: ROAPAC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-71: ROW: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE-72: ROW: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE-73: ROW: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE-74: PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS (2013-2016)
  • TABLE-75: DIVESTMENTS AND ACQUISITIONS (2013-2016)
  • TABLE-76: GEOGRAPHIC EXPANSIONS (2013-2016)
  • TABLE-77: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2013-2016)
  • TABLE-78: OTHER DEVELOPMENTS (2013-2016)

LIST OF FIGURES

  • FIGURE-1: RESEARCH DESIGN
  • FIGURE-2: NUMBER OF NEW CANCER CASES, BY COUNTRY: 2012 VS. 2020
  • FIGURE-3: INCREASING INCIDENCES OF CANCERS, BY SITE: 2012-2020
  • FIGURE-4: INCREASE IN AGING POPULATION, BY COUNTRY: 2010 VS. 2015
  • FIGURE-5: PERCENTAGE INCREASE IN AGING POPULATION, BY REGION: (1980-2010) VS. (2010-2040)
  • FIGURE-6: HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES: 2000-2014
  • FIGURE-7: HEALTHCARE EXPENDITURE ACROSS MAJOR REGIONS: 2000-2014
  • FIGURE-8: SIGNIFICANT AVAILABILITY OF PUBLIC-PRIVATE INVESTMENTS TO SUPPORT TUMOR ABLATION-BASED RESEARCHES: LED BY U.S., CHINA AND EUROPE
  • FIGURE-9: TUMOR ABLATION IS EXPECTED TO BE THE FASTEST-GROWING ABLATION TECHNOLOGY APPLICATION SEGMENT TILL 2021
  • FIGURE-10: NUMBER OF NEW PRODUCT LAUNCHES: TUMOR ABLATION MARKET (2013-2016)
  • FIGURE-11: MARKET SIZE ESTIMATION
  • FIGURE-12: TUMOR ABLATION MARKET , BY COUNTRY/REGION (2016-2021)
  • FIGURE-13: TUMOR ABLATION MARKET: REGIONAL SCENARIO (2016)
  • FIGURE-14: GLOBAL TUMOR ABLATION MARKET FUTURE TRENDS, BY MODE OF TREATMENT AND APPLICATION (2016-2021)
  • FIGURE-15: GLOBAL PREVALENCE OF CANCER: EXPECTED TREND FOR 2012 VS. 2015 VS. 2020
  • FIGURE-16: KEY TUMOR ABLATION MARKETS: CHANGING PROPORTION OF GERIATRIC INDIVIDUALS IN THE TOTAL POPULATION (2012 VS. 2020)
  • FIGURE-17: PERCENTAGE CHANGE IN HEALTHCARE EXPENDITURE: DEVELOPED VS. DEVELOPING NATIONS (2005-2014)
  • FIGURE-18: TUMOR ABLATION MARKET, BY TECHNOLOGY: GROWTH FORECAST DURING 2016-2021
  • FIGURE-19: TUMOR ABLATION MARKET SHARE FOR RF TECHNOLOGY, BY REGION (2016)
  • FIGURE-20: TUMOR ABLATION MARKET SHARE FOR MICROWAVE TECHNOLOGY, BY REGION (2016)
  • FIGURE-21: TUMOR ABLATION MARKET SHARE FOR CRYOABLATION TECHNOLOGY, BY REGION (2016)
  • FIGURE-22: TUMOR ABLATION MARKET SHARE FOR OTHER TECHNOLOGIES, BY REGION (2016)
  • FIGURE-23: TUMOR ABLATION MARKET, BY MODE OF TREATMENT: GROWTH FORECAST DURING 2016-2021
  • FIGURE-24: TUMOR ABLATION MARKET FOR SURGICAL MODE OF TREATMENT, BY REGION (2016)
  • FIGURE-25: TUMOR ABLATION MARKET FOR LAPAROSCOPIC MODE, BY REGION (2016)
  • FIGURE-26: TUMOR ABLATION MARKET FOR PERCUTANEOUS MODE, BY REGION (2016)
  • FIGURE-27: TUMOR ABLATION MARKET, BY APPLICATION: GROWTH FORECAST DURING 2016-2021
  • FIGURE-28: TUMOR ABLATION MARKET SHARE FOR LIVER CANCER, BY REGION (2016)
  • FIGURE-29: TUMOR ABLATION MARKET SHARE FOR LUNG CANCER, BY REGION (2016)
  • FIGURE-30: TUMOR ABLATION MARKET SHARE FOR KIDNEY CANCER, BY REGION (2016)
  • FIGURE-31: TUMOR ABLATION MARKET SHARE FOR BONE METASTASIS, BY REGION (2016)
  • FIGURE-32: TUMOR ABLATION MARKET SHARE FOR OTHER APPLICATIONS, BY REGION (2016)
  • FIGURE-33: NORTH AMERICAN TUMOR ABLATION MARKET: EXPECTED TRENDS (2016 VS. 2021)
  • FIGURE-34: NORTH AMERICA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-35: U.S.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-36: U.S.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-37: U.S.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-38: CANADA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-39: CANADA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-40: CANADA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-41: EUROPEAN TUMOR ABLATION MARKET: EXPECTED TRENDS (2016 VS. 2021)
  • FIGURE-42: EU5: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-43: ITALY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-44: ITALY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-45: ITALY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-46: GERMANY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-47: GERMANY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-48: GERMANY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-49: FRANCE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-50: FRANCE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-51: FRANCE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-52: U.K.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-53: U.K.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-54: U.K.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-55: SPAIN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-56: SPAIN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-57: SPAIN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-58: ROE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-59: ROE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-60: ROE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-61: ASIA-PACIFIC TUMOR ABLATION MARKET: EXPECTED TREND (2016 VS. 2021)
  • FIGURE-62: ASIA-PACIFIC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-63: JAPAN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-64: JAPAN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-65: JAPAN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-66: CHINA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-67: CHINA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-68: CHINA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-69: INDIA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-70: INDIA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-71: INDIA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-72: ROAPAC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE-73: ROAPAC: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE-74: ROAPAC: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE-75: ROW TUMOR ABLATION MARKET: EXPECTED TREND (2016 VS. 2021)
  • FIGURE-76: LEADING MARKET PLAYERS ADOPTED PRODUCT DEVELOPMENT AND COMMERCIALIZATION AS KEY GROWTH STRATEGIES DURING 2013-2016
  • FIGURE-77: TUMOR ABLATION MARKET SHARE, BY KEY PLAYER (2015)
  • FIGURE-78: KEY GROWTH STRATEGIES, BY YEAR (2013-2016)
  • FIGURE-79: PRODUCT DEVELOPMENT, THE MOST WIDELY ADOPTED GROWTH STRATEGY DURING 2013-2016
  • FIGURE-80: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS: TUMOR ABLATION MARKET (2015)
  • FIGURE-81: PIPELINE DEVELOPMENT AND PRODUCT ENHANCEMENT IS THE KEY STRATEGY PURSUED BY TOP PLAYERS TO INCREASE THEIR TUMOR ABLATION MARKET REVENUE  
Back to Top